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Abstract
Background: Leucine may function as a signaling molecule to regulate metabolism. We have previously shown that 
dietary leucine supplementation significantly improves glucose and energy metabolism in diet-induced obese mice, 
suggesting that leucine supplementation could potentially be a useful adjuvant therapy for obesity and type 2 
diabetes. Since the underlying cause for obesity and type 2 diabetes is multifold, we further investigated metabolic 
effects of leucine supplementation in obese/diabetes mouse models with different etiologies, and explored the 
underlying molecular mechanisms.
Methods: Leucine supplementation was carried out in NONcNZO10/LtJ (RCS10) - a polygenic model predisposed to 
beta cell failure and type 2 diabetes, and in B6.Cg-Ay/J (Ay) - a monogenic model for impaired central melanocortin 
receptor signaling, obesity, and severe insulin resistance. Mice in the treatment group received the drinking water 
containing 1.5% leucine for up to 8 months; control mice received the tap water. Body weight, body composition, 
blood HbA1c levels, and plasma glucose and insulin levels were monitored throughout and/or at the end of the study 
period. Indirect calorimetry, skeletal muscle gene expression, and adipose tissue inflammation were also assessed in Ay 
mice.
Results: Leucine supplementation significantly reduced HbA1c levels throughout the study period in both RCS10 and 
Ay mice. However, the treatment had no long term effect on body weight or adiposity. The improvement in glycemic 
control was associated with an increased insulin response to food challenge in RCS10 mice and decreased plasma 
insulin levels in Ay mice. In leucine-treated Ay mice, energy expenditure was increased by ~10% (p < 0.05) in both dark 
and light cycles while the physical activity level was unchanged. The expression levels of UCP3, CrAT, PPAR-alpha, and 
NRF-1, which are known to regulate mitochondrial oxidative function, were significantly increased in the soleus muscle 
of leucine-treated Ay mice whereas the expression levels of MCP-1 and TNF-alpha and macrophage infiltration in 
adipose tissue were significantly reduced.
Conclusions: Chronic leucine supplementation significantly improves glycemic control in multiple mouse models of 
obesity and diabetes with distinct etiologies. The metabolic benefits of leucine supplementation are likely mediated 
via multiple mechanisms in different tissues, but are not necessarily dependent of weight reduction.
Background
Impaired glucose metabolism and type 2 diabetes are
prevalent metabolic disorders, and are commonly associ-
ated with obesity. Considerable interest has been gener-
ated in recent years in dietary approaches for the
prevention and treatment of obesity and the associated
insulin resistance and diabetes mellitus because the inter-
action between diet and genetic predisposition plays a
significant role in the development of these metabolic
disorders. In obese and insulin resistant individuals, pro-
tein-rich diets are associated with better glycemic control
and plasma lipid profile, and, when used therapeutically
for weight reduction, promote energy expenditure and
greater relative fat reduction, compared to isocaloric,
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high carbohydrate or high fat diets [1-5]. However, the
molecular mechanism for the observed metabolic bene-
f i t s  o f  p r o t e i n - r i c h  d i e t  i s  n o t  f u l l y  u n d e r s t o o d .  I t  h a s
been postulated that increased intake of leucine, an
essential branched-chain amino acid (BCAA) and a natu-
ral component of dietary proteins, may play an important
role in mediating the metabolic benefits of protein-rich
diet [6,7]. Indeed, increasing evidence suggests that
altered leucine/BCAA intake and metabolism could have
significant effects on macromolecule and energy metabo-
lism. Genetic knockout of branched-chain aminotrans-
ferase 2 (BCATm), which catalyzes the first step of BCAA
catabolism, leads to dramatically elevated plasma levels of
BCAAs, increased energy expenditure, and lean pheno-
type in mice [8]. Leucine supplementation with 50% food
restriction results in lower adiposity in rats, compared to
the control animals that are subjected to the same 50%
food restriction without leucine supplementation [9].
Chronic supplementation with BCAAs also increases
hepatic and muscle glycogen concentration in exercised
rats [10]. However, metabolic effects of leucine and/or
BCAA supplementation may be complex, and some of
the beneficial effects have not always been seen. Newgard
e t  a l  r e p o r t e d  t h a t  d i e t a r y  s u p p l e m e n t a t i o n  o f  B C A A
reduces high fat diet-induced weight gain in mice, but
induces insulin resistance [11].
We have investigated whether dietary leucine supple-
mentation is able to mimic the effects of protein-rich diet
on glucose and energy metabolism in C57BL/6J mice on a
high fat diet (DIO mice) [7]. We have shown that dou-
bling dietary leucine intake over a 14-week period signifi-
cantly increases energy expenditure, attenuates high fat
diet-induced weight gain, and improves glucose and cho-
lesterol metabolism in these DIO mice [7]. However,
given the complexity of the underlying causes for obesity
and type 2 diabetes and of the potential effects of leucine
and/or BCAA on energy and glucose metabolism [7-
9,11,12], we sought in this study to further investigate the
metabolic effects of long term leucine supplementation in
two additional mouse models of obesity and diabetes
with distinct etiologies and disease severities, and to
explore the underlying molecular mechanisms.
NONcNZO10/LtJ (RCS10), a congenic strain generated
by combining quantitative trait loci from New Zealand
Obese (NZO/HlLt) and nonobese nondiabetic (NON/
LtJ) mice, is a recently established polygenic mouse
model of obesity and type 2 diabetes [13]. Although the
exact nature of the quantitative traits loci responsible for
the obesity and diabetes phenotype of RCS10 is not yet
fully defined, the polygenic nature and the relatively mild
obesity of this model closely resemble human type 2 dia-
betes. Male RCS10 mice are characterized by maturity-
onset obesity, hepatic insulin resistance, beta cell failure,
and full-fledged diabetes around 6 months of age if they
are put on a diet containing ~20% calories from fat
[13,14]. The second model studied is B6.Cg-Ay/J (Ay),
which segregates for a mutation (yellow) in the agouti
gene that impairs melanocortin receptor signaling
(MC3R and MC4R) in the central nervous system [15]. In
the C57BL/6J inbred background, male Ay mice are mildly
hyperphagic, hypometabolic, and extremely insulin resis-
tant. Although male Ay mice are glucose intolerant, they
rarely develop frank diabetes due to strong beta-cell com-
pensations. Thus, the Ay model, compared to the RCS10
model, represents the other end of the spectrum of
impaired glucose homeostasis, in which insulin resistance
dominates the disease process.
Materials and Methods
Animal husbandry, diets and leucine supplementation
Seven to eight-week-old male NONcNZO10/LtJ (RCS10)
and B6.Cg-Ay/J (Ay) mice were purchased from Jackson
Laboratories. Animal protocols were in compliance with
the accepted standards of animal care, and were approved
by the Columbia University Institutional Animal Care
and Use Committee. Mice were maintained at 22°C on a
12:12 light-dark cycle (0700-1900), and had ad libitum
access to the breeder chow (Purina Mouse Diet 20 5058,
21.8%, 21.6% and 56.6% calories from protein, fat, and
carbohydrates, respectively). The breeder chow diet,
which contains twice as much fat calories as the regular
chow, increases the rate of weight gain in Ay mice and is
necessary for the development of overt diabetes with high
frequency in male RCS10 mice (Jackson Laboratory web-
site). Leucine was supplemented via the drinking water
containing 1.5% (wt vol-1) L-leucine (Sigma, St. Louis,
MO) as previously described [7,16]. Since rodents con-
sume the majority of water with meals during the dark
cycle, supplementation via drink water should achieve
similar effects as supplementation through food. This
method of supplementation was chosen mainly out of the
consideration of convenience. The controls were sex- and
age-matched mice fed the same diet with regular tap
water as drinking water.
Determination of body composition, plasma amino acid 
concentrations, and blood HbA1c, glucose and insulin 
levels
Body composition was determined using a Minispec TD-
NMR Spectrometer (Bruker Optics, TX). HbA1c levels
were determined using DCA 2000 Hemoglobin A1c
(HbA1c) Reagent Kit (Bayer, HealthCare, LLC, Elkhart,
IN). Plasma amino acid concentrations were determined
by the Hormone Analytic Core of the Mouse Metabolic
Phenotyping Center at the Vanderbilt University. Blood
glucose levels were measured in tail-vein blood using
Glucometer Elite (Bayer, Elkhart, IN). Plasma insulin lev-
els were determined using an ELISA kit (Mercodia Inc,Guo et al. Nutrition & Metabolism 2010, 7:57
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Winston Salem, NC). Because plasma glucose and insulin
levels are regulated by different mechanisms in different
feeding states, we measured them in three feeding states
to assess the effect of leucine treatment on these mecha-
nisms. The three feeding states are defined as: the fed
state - measurements were taken at the 4th hour of the
dark cycle; the basal state - measurements were taken at
the 7th hour of the light cycle after 5 hour food and leu-
cine deprivation; the fast state - measurements were
taken after 24 hour food and leucine deprivation. During
the food and leucine deprivation, all mice were supplied
with the regular tap water to prevent them from dehydra-
tion. In order to minimize the effects of feeding manipu-
lation and handling (collecting ~50 ul blood for insulin
analysis) on their metabolism, the mice were tested in the
three feeding states in the following order, the fed state,
the basal state, and the fast state during the testing period
after 2, 4 or 8 month leucine treatment. A 2-day resting
period was given between testing, and the animals were
allowed to recover from the 24 hour fast for at least one
week. The interpretations of the data obtained in the dif-
ferent feeding states are described in the text where they
are relevant. To further compare the regulation of glu-
cose-insulin homeostasis in response to acute meal inges-
tion in leucine-treated and control mice, we also
conducted a fasting-refeeding experiment in RCS10 mice
at the end of 8 month leucine treatment. The mice in
both leucine and control groups were deprived of food
and leucine (for the leucine group) and supplied with the
regular tap water for 24 hours (11 am-11 am). Food was
then re-introduced with the regular tap water and 1.5%
leucine solution for the control and leucine groups,
respectively. The mice were allowed to feed ad lib for 3
hours before bloods were collected for determination of
plasma glucose and insulin. Food and water intake during
the 3 hour refeeding period were recorded.
Measurement of food intake and indirect calorimetry
Daily food intake and water (or leucine solution) con-
sumption were determined twice a week in individually-
housed mice during the first two months of leucine treat-
ment in both RCS10 and Ay mice. Indirect calorimetry
was performed in Ay mice at the end of 4 month leucine-
treatment (LabMaster, TSE Systems, Inc. Chesterfield
MO). Oxygen consumption, locomotive activity, respira-
tion exchange ratio (RER, VCO2/VO2), and food intake
were measured continuously during the same 12:12 light-
dark cycles. The same diet and leucine regimens were
continued during indirect calorimetry. Data were col-
lected over a 3 day period following 2 days of adaptation
to the metabolic cage.
Determination of mRNA expression
Quantitative real-time RT-PCR was used to determine
mRNA expression as previously described [17]. Briefly,
total RNA was isolated using RNAeasy mini-columns
(Qiagen, CA), and reverse-transcribed into single-
stranded cDNA using random hexamers and M-MLV
Reverse Transcriptase (Invitrogen, CA). Quantitative
amplification by polymerase chain reaction (PCR) was
carried out using Bio-Rad iQ SYBR Green Supermix (Bio-
Rad Laboratories, CA). All RT-PCR reactions were done
in duplicates. Cyclophilin A mRNA level was used to nor-
malize total RNA input. Cycle numbers at a set fluores-
cence threshold within the exponential amplification
range (Ct) were used to calculate expression levels of the
genes of interest (relative to cyclophilin A). Changes in
gene expression in leucine-treated mice were expressed
relatively the control values. Following gene-specific
primers were used for mRNA quantification in this study:
cyclophilin A, 5'-atggcactggcggcaggtcc-3' (forward), 5'-
ttgccattcctggacccaaa-3' (reverse); UCP3, 5'-caagggagcg-
gaccactcc-3' (forward) 5'-ctctctcctccagttcccatg-3'
(reverse); CrAT, 5'- tgccagttgagttcctggga-3', 5'- tctgatct-
gaggtgagcggt-3' (reverse); CPT-1B, 5'-ggcaacagttggttcca-
actact-3' (forward), 5'-caggaagcttaggcatgtacgtt-3'
(reverse); PPAR-alpha, 5'-tcatacatgacatggagaccttg-3' (for-
ward), 5'-actggcagcagtggaagaatc-3' (reverse); NRF-1, 5'-
ggagcacttactggagtcc-3' (forward), 5'-ctgtccgatatcctggtggt-
3' (reverse); NRF-2, 5'-ggggaacagaacaggaaaca-3' (for-
ward), 5'-ccgtaatgcacggctaagtt-3' (reverse); TBP, 5'-ggc-
ctctcagaagcatcacta-3' (forward), 5'-gccaagccctgagcataa-3'
(reverse); aP2, 5'-gacgacaggaaggtgaagagc-3' (forward), 5'-
gcctttcataacacattccacc-3' (reverse); leptin, 5'-tgacacca-
aaaccctcatca-3' (forward), 5'-agcccaggaatgaagtcca-3'
(reverse); MCP-1, 5'-ctgaagccagctctctcttcct-3' (forward),
5'-tccttcttggggtcagcacaga-3' (reverse); TNF-alpha, 5'-cca-
ccacgctcttctgtcta-3' (forward), 5'-agctgctcctccacttggtg-3'
(reverse); F4/80, 5'-ctttggctatgggcttccagtc-3' (forward), 5'-
gcaaggaggacagagtttatcgtg-3' (reverse).
Immunohistochemical analysis of adipose tissue
Adipose tissue was fixed in 4% paraformaldehyde for 3
days and then paraffin-embedded according to the stan-
dard procedure. Tissue sections (7 um) were stained with
anti mouse F4/80 antibody (Cat # MF8000, Invitrogen,
CA) and then counter-stained with hematoxylin as previ-
ously described [18]. The level of macrophage infiltration
was assessed by visual examination of the positive stain-
ing under the light microscopy.
Statistical analysis
A l l  d a t a  w e r e  e x p r e s s e d  a s  m e a n  ±  S E M .  D i f f e r e n c e s
between leucine-treated and control mice were assessed
using t-tests (STATISTICA V6, StatSoft, Tulsa, OK). A 2-
tailed p < 0.05 was considered statistically significant.
Correlation analysis was used to assess relationships
between HbA1C and plasma glucose and insulin levels.
Results
Long term leucine supplementation prevents the 
development of overt diabetes in RCS10 mice
Leucine supplementation was started in 8-week-old
RCS10 mice and lasted for 8 months. The average waterGuo et al. Nutrition & Metabolism 2010, 7:57
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consumption measured during the first two months was
not significantly different between the control (7.8 ± 0.2
ml/day) and leucine group (7.6 ± 0.1 ml/day). The average
leucine intake via drinking water was 114.5 ± 15 mg/day,
1.9-fold the daily leucine intake from the chow during
this period. Food intake during the first 2 months of
treatment was significantly lower in leucine-treated mice
(3.80 ± 0.14 g/day), relative to the control mice (4.19 ±
0.16 g/day) (p < 0.05) (Fig 1A). Weight gain during this
period was also reduced in leucine-treated mice (10.1 ±
0.66 g vs. 13.1 ± 0.41 g, p < 0.01) (Fig 1B). However, no
significant difference in body weight or adiposity was
observed between the leucine-treated and control mice at
the end of 4 and 8 month treatment (Fig 1B-1C).
HbA1c levels were significantly lower in leucine-
treated RCS10 mice relative to the control mice at the end
of 2, 4, and 8 month treatment (p < 0.05 at all points) (Fig
1D). At the end of 8-month study period, more than 50%
of the control mice developed overt diabetes with HbA1c
levels greater than 9%, while none of the leucine-treated
mice had HbA1c levels greater than 7.8%. The average
HbA1c levels at 8 month were 8.68 ± 0.60% (ranging from
6.2%-10.4%) in the control groups and 6.67 ± 0.41% in the
leucine group (ranging from 4.7%-7.8%). Blood glucose
levels were also significantly lower or trended lower in
leucine-treated RCS10 mice, compared to the control
mice in all of the feeding states (Fig 2A). Basal and fast
insulin levels were not significantly different at the end of
8 month-study (Fig 2B), but insulin secretion in response
to refeeding was significantly more robust in leucine-
treated mice than in control mice (Fig 2B). Three-hour
refeeding following a 24 hr fast resulted in an average
15.8-fold increase (over the fast level) in plasma insulin
levels in leucine-treated mice (ranging from 6.1 to 29.6
fold), but only 6.5-fold increase in control mice (ranging
from 2.8 to 10.0 fold) (p < 0.05). The absolute plasma
insulin levels after the 3 hour refeeding were also signifi-
cantly higher in leucine-treated mice (29.5 ± 5.5 vs. 11.0 ±
2.1 ng/ml, p < 0.01). Food intake during the refeeding
period was not significantly different between the groups
(1.23 ± 0.05 vs. 1.37 ± 0.15 g). Plasma leucine concentra-
tion was 38.6% (p < 0.05) higher in leucine-treated mice
than in the control mice after the 3 hour refeeding; the
concentrations of other amino acids examined were not
significantly different between the two groups (Fig 2C).
To further examine the relationship between glycemic
control and beta cell function in RCS10 mice at the end of
8 month leucine treatment, HbA1c levels were related to
plasma glucose and insulin levels after the 3 hour refeed-
ing. HbA1c levels were positively correlated with the fed
plasma glucose levels (r = 0.78, p < 0.001) (Fig 2D). The
plotting of HbA1c levels against plasma insulin levels (Fig
2E) revealed that beta-cell decompensation was most
conspicuous in the mice with HbA1c levels >9.0% (circled
data points in Fig 2D and 2E), all of which were in the
control group. These results suggest that the improve-
ment in glycemic control in leucine-treated RCS10 mice
may be attributable in part to the increased insulin
response to feeding and decreased postprandial plasma
glucose levels.
Long term leucine supplementation improves glucose-
insulin homeostasis in yellow agouti (Ay) mice independent 
of weight reduction
Metabolic effects of leucine supplementation were exam-
ined in two age groups of Ay mice. In the first group, the
treatment was started at 8 weeks of age and lasted for 4
months. The average food intake (3.99 ± 0.10 vs. 4.21 ±
0.09 g/day) and water consumption (7.3 ± 0.6 vs. 7.5 ± 0.7
ml/day) during the first two months of treatment were
not significantly different between leucine-treated Ay
mice and their controls. Body weight was not signifi-
cantly different between the control and leucine groups
after 2 and 4 months of treatment (Fig 3A), nor was the
body composition (data not shown). Again, HbA1c levels
were significantly lower in leucine-treated mice than in
control mice after 2 months (4.8 ± 0.3% vs. 5.7 ± 0.5%, p <
0.05) and 4 months (6.3 ± 0.2% vs. 7.2 ± 0.3%, p < 0.05)
(Fig 3B). Effects of leucine supplementation on body
weight and HbA1c levels were similar in the second
group of Ay mice (old Ay), in which the treatment was
started at 5 months of age and lasted for 10 weeks. At the
end of the 10-week treatment, body weight was not sig-
nificantly different between the control and leucine
groups (Fig 3C), but the HbA1c level was significantly
Figure 1 Leucine supplementation improves glycemic control in-
dependent of energy balance in NONcNZO10/LtJ (RCS10) mice. A: 
The average daily food intake measured during the first two months of 
leucine-treatment. B-D: Body weight (B), body composition (C), and 
HbA1c levels (D) in the control and leucine-treated RCS10 mice before 
(0 mo) and after 2, 4, and 8 months of leucine-treatment. * indicates p 
< 0.05, control vs. leucine-treated, n = 7.
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lower in leucine-treated mice, relative to the control mice
(p < 0.05) (Fig 3D). While the HbA1c level rose from 4.2%
to 6.4% in the control group during this period, it was vir-
tually unchanged in the leucine-treated group (4.3% to
4.6%).
Fed plasma glucose levels were also significantly lower
in leucine-treated Ay mice than in control mice at the end
of 4 month treatment (p < 0.01) (Fig 4A), and were posi-
tively correlated with the HbA1c levels in these mice (r =
0.73, p < 0.001) (Fig 4B). Although basal and fast blood
glucose levels were not significantly different between the
control and leucine groups, the corresponding plasma
insulin levels were 38.5% and 33.9% lower, respectively, in
leucine-treated mice, relative to the control mice (both p
Figure 2 Leucine supplementation improves glucose and insulin homeostasis and prevents overt diabetes in RCS10 mice. A: Plasma glucose 
levels in the fed (or after 3 hour refed), basal (after five hour of food and leucine deprivation), and fast states in the control and leucine-treated RCS10 
mice after 4 or 8 months of leucine-treatment. B: Plasma insulin levels in the refed, basal, and fast states in the control and leucine-treated mice at the 
end of 8 month study. C: Plasma concentrations of leucine and other amino acids after 3 hour-refeeding. D: The relationship between HbA1c levels 
and plasma glucose levels after the refeeding. There was a significant correlation between the two parameters (F = 29.46, p < 0.001), which fits the 
following equation (refed glu = -284 + 69.58x HbA1c, Standard error of estimation is 80.245). E: The relationship between HbA1c levels and plasma 
insulin levels after 3 hr refeeding. There was no statistically significant correlation between HbA1c levels and refed plasma insulin levels at the end of 
8 month treatment. Beta cell decompensation was evident in the mice with overt diabetes (HbA1c > 9%, circled). * and ** indicate p < 0.05 and 0.01, 
control vs. leucine-treated, respectively, n = 7.
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< 0.05) (Fig 4C-4D), suggesting that leucine supplementa-
tion may have improved insulin sensitivity in the basal
and fast states in these mice. Plasma insulin levels in the
fed state did not differ significantly between the control
and leucine groups (0.80 ± 0.11 vs. 1.11 ± 0.21 μg ml-1, p =
0.16) (Fig 4E).
Leucine supplementation increases metabolic rates and 
the expression of genes involved in energy metabolism in 
skeletal muscle
In order to determine the effect of long term leucine sup-
plementation on energy metabolism, indirect calorimetry
was performed in the Ay mice at the end of 4 month leu-
cine-treatment. Rates of oxygen consumption were
~10.7% and 8.9% higher, respectively, in the light and dark
cycles in leucine-treated mice, relative to control mice
(both p < 0.05) (Fig 5A). No increase in locomotive activ-
ity in leucine-treated mice was observed (F ig 5B). T he
respiratory exchange ratio (RER, VCO2/VO2) was slightly
lower and food intake was slight higher in leucine-treated
mice, compared to the control mice, although the differ-
ences were not statistically significant (Fig 5C-5D).
In order to further understand the effect of leucine sup-
plementation on energy metabolism at the molecular
level, we next examined the expression level of key genes
involved in fatty acid metabolism and mitochondrial
function in the skeletal muscle of Ay mice. The mRNA
levels for uncoupling protein 3 (UCP3), carnitine acetyl-
transferase (CrAT), peroxisome proliferators-activated
receptor alpha (PPAR-alpha), and nuclear respiratory fac-
tor 1 (NRF-1) were significantly higher in the soleus mus-
cle of leucine-treated mice than in control mice (Fig 6).
The mRNA levels for carnitine palmitoyltransferase-1B
(CPT-1B) and nuclear respiratory factor 2 (NRF-2) were
Figure 5 Leucine supplementation increases the resting meta-
bolic rates in Aymice. A-C: rates of oxygen consumption (A), locomo-
tive activities (B) and respiratory exchange ratio (RER, VCO2/VO2) (C) in 
the light and dark cycles in young Ay mice at the end of 4 month treat-
ment. D. Food intake per unit of fat-free body mass (FFM) during the 
indirect calorimetric analysis. * indicates p < 0.05, control vs. leucine-
treated, n = 8.
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Figure 3 Leucine supplementation improves glycemic control in-
dependent of energy balance in yellow agouti (Ay) mice. A-B: Body 
weight (A) and HbA1c levels (B) of the young Ay mice before and after 
2 and 4 months of leucine treatment. Leucine supplementation and 
breeder chow diet were started at 2 months of age (n = 8). C-D: Body 
weight (C) and HbA1c levels (D) of the old Ay mice before and after 10 
weeks of leucine treatment. Leucine supplementation and breeder 
chow diet were started at 5 months of age (n = 6). * indicates p < 0.05, 
control vs. leucine-treated at the end of the study.
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also increased although the differences were not statisti-
cally significant. The expression level of TATA-binding
protein (TBP) was unaltered. These results suggest that
long term leucine treatment may increase energy expen-
diture by selectively stimulating the expression of a set of
key genes involved in fatty acid metabolism and mito-
chondrial biogenesis in the skeletal muscle.
Long term leucine-supplementation decreases adipose 
tissue inflammation in Ay mice
Obesity and insulin resistance have been associated with
adipose tissue inflammation in both humans and rodents
[18-22]. In order to assess the effect of leucine supple-
mentation on adipose tissue inflammation, we examined
the expression of several proinflammatory markers and
macrophage infiltration in leucine-treated and control Ay
mice. Messenger RNA levels of monocyte chemoattrac-
tant protein-1 (MCP-1), tumor necrosis factor-alpha
(TNF-alpha), and F4/80, a specific marker of mac-
rophage, were significantly decreased in the epididymal
adipose tissue of leucine-treated Ay mice, relative to the
control mice (Fig 7A). In contrast, mRNA levels of two
adipocyte-specific genes, aP2 and leptin, were not signifi-
cantly different between the two groups (Fig 7A). Consis-
tent with the decreased mRNA expression of F4/80 gene,
immunostaining of the epididymal adipose tissue with
anti-mouse F4/80 antibody confirmed that the degree of
macrophage infiltration in the epididymal adipose tissue
was also decreased in leucine-treated Ay mice, relative to
the control mice (Fig 7B). These results suggest that long
term leucine supplementation may attenuate adipose tis-
sue inflammation associated with obesity.
Discussion
We have shown in the current study that dietary leucine
supplementation significantly improves glucose-insulin
homeostasis in two etiologically distinct mouse models of
obesity/diabetes, RCS10 and Ay, even though the treat-
ment has no long term effect on energy balance in these
mouse models. We have further shown that the metabolic
benefits of leucine supplementation in Ay mice are associ-
ated with increased resting metabolic rates, reduced adi-
pose tissue inflammation, and increased expression of
genes involved in regulating energy metabolism and
mitochondrial function in the skeletal muscle.
A novel finding of the study is that long term leucine
supplementation prevents the development of full-
fledged diabetes in RCS10 mice, which are prone to beta
cell failure [13]. More than 50% of the control mice devel-
oped severe diabetes mellitus (HbA1c > 9%) at 10 months
of age, but none of the leucine-treated mice had HbA1c
higher than 7.8%. We found that leucine-treated RCS10
mice, relative to the control mice, demonstrated ~ 2-fold
Figure 7 Leucine supplementation decreases adipose tissue in-
flammation in Ay mice. A: messenger RNA levels of aP2, leptin, mono-
cyte chemoattractant protein-1 (MCP-1), tumor necrosis factor alpha 
(TNF-alpha), and F4/80, a macrophage-specific marker, in the epididy-
mal adipose tissue of leucine-treated and control young Ay mice at the 
end of 4 month study period. The expression levels in leucine-treated 
mice are expressed relatively to the levels of the control mice. * and ** 
indicate p < 0.05 and 0.01, respectively, control vs. leucine-treated, n = 
8. B. Immunohistochemical staining of F4/80 of epididymal adipose tis-
sue of leucine-treated and control young Ay mice. The arrows indicate 
the nuclei positive for F4/80 staining.
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increase in insulin response to food challenge, suggesting
that leucine supplementation may have direct effects on
postprandial insulin secretion. We found that while food
intake during the refeeding period was not significantly
different between the two groups, leucine supplementa-
tion resulted in 38.6% increase in plasma leucine concen-
tration in RCS10 mice at the end of 3 hour refeeding, a
result similar to that observed in the DIO mouse model
in our previous study [7]. Since leucine is a known insulin
secretagogue [23-26], elevated postprandial plasma leu-
cine level may be in part responsible for the more robust
insulin response to feeding in RCS10 mice. Additionally,
the lower plasma glucose levels in the presence of similar
plasma insulin levels in leucine-treated RCS10 mice in
the basal and fast states suggests that leucine supplemen-
tation may also improve hepatic insulin sensitivity in
these mice, which is known to develop hepatic insulin
resistance [13,14,27,28]. The increased postprandial insu-
lin secretion and the apparently improved hepatic insulin
sensitivity may both contribute to the better glycemic
control and prevention of full-fledged diabetes in leucine-
treated RCS10 mice.
In Ay mice, which develop severe insulin resistance but
have robust beta-cell compensations, leucine supplemen-
tation also appears to improve insulin sensitivity. Plasma
insulin levels were lower in leucine-treated Ay mice than
in the control mice in all of the feeding states at the end of
4 month treatment. The lower plasma insulin levels,
together with the lower HbA1c and/or plasma glucose
levels are suggestive of an improvement of insulin sensi-
tivity in these mice. Furthermore, the effects of leucine
supplementation on glucose and insulin homeostasis in
Ay mice are consistent with those observed in our previ-
ous study - insulin and glucose tolerance tests have
shown that leucine supplementation improves insulin
sensitivity and glucose tolerance in DIO mice [7].
Leucine supplementation significantly decreased adi-
pose tissue inflammation in Ay mice, which could be an
important mechanism for the improved glucose metabo-
lism in these mice as adipose tissue inflamma tion and
increased expression of pro-inflammatory cytokines have
been implicated in causing insulin resistance
[18,19,22,29-31]. We found that adipose tissue expression
of pro-inflammatory cytokines and macrophage infiltra-
tion were both decreased in the epididymal adipose tissue
of leucine-treated Ay mice, relative to the control mice.
Mechanism for the decreased adipose tissue inflamma-
tion in leucine-treated mice remains to be investigated.
Activation of mTORC1 has also been shown to sup-
presses inflammation and lipolysis [32,33], two of the
known risk factors for obesity-associated insulin resis-
tance [29,34-36]. It is conceivable that long term leucine
supplementation may lead to chronic, low grade activa-
tion of mTORC1, which in turn suppresses fatty acid
release and inflammation, resulting in improved insulin
sensitivity in the obese mice.
Long term leucine supplementation also has significant
effects on energy metabolism in Ay mice. Oxygen con-
sumption was increased in both light and dark cycles in
the absence of increased locomotive activity in Ay mice,
suggesting that leucine supplementation increases the
resting metabolic rate in these mice. Similar increases in
the resting metabolic rate are also observed in leucine-
treated DIO mice as we have previously reported [7]. As
in the DIO mice and RCS10 mice, plasma leucine concen-
tration was likely elevated only in the fed state but not in
the basal state in Ay mice. Thus, it appears that in these
obese mouse models chronic dietary leucine supplemen-
tation increases energy expenditure independent of the
acute effects of meal or leucine ingestion. The increases
in the expression of UCP3, CrAT, PPAR-alpha, and NRF-
1 in the skeletal muscle of leucine-treated Ay mice further
support this notion. Consistent with the data in Ay mice,
significant increases in the expression of the above genes
as well as NRF-2 are also observed in the soleus muscle of
leucine-treated DIO mice, relative to their respective
controls, after 14 weeks of leucine treatment (unpub-
lished observation). Many studies have shown that obe-
sity and insulin resistance are commonly associated with
impaired fatty acid oxidation and mitochondrial function
[36-41]. Thus, improved energy metabolism and mito-
chondrial oxidative function could be an important
mechanism for the improvements in glucose-insulin
homeostasis in leucine-treated mice. The effect of leucine
supplementation on the resting metabolic rate in both Ay
and DIO mice bears a striking resemblance to that of pro-
tein-rich diets [42,43], and is supportive of the postula-
tion that leucine is a key mediator of the metabolic
benefits of protein-rich diet [6,7].
The effects of chronic leucine supplementation on
energy balance are complex. As discussed above, leucine
supplementation increases metabolic rates in both Ay
mice and DIO mice [7]. We also found that food intake
and the rate of weight gain were significantly lower in leu-
cine-treated RCS10 mice, relative to the controls, during
the first 2 months of treatment. The initial suppressive
effect of leucine on food intake is not entirely unexpected
as acute central administration of leucine has been shown
to suppress food intake and body weight in rats [44,45].
However, despite these changes, body weight and adipos-
ity were not significantly different in either RCS10 or Ay
mice at the end of the study period. It is possible that the
lack of long term effects of leucine supplementation on
energy balance in RCS10 and Ay mice may be due in part
to compensatory changes in energy intake in the later
phase of treatment. As many previous studies have also
shown, the regulation of energy balance in humans andGuo et al. Nutrition & Metabolism 2010, 7:57
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rodents is redundant and compensatory changes occur
when energy balance is perturbed. Furthermore, such
compensatory changes appear to be strongly biased
against negative energy balance (see [46,47] for review).
Indeed, the increase in the metabolic rate in leucine-
treated  Ay mice at the end of 4-month treatment was
accompanied by a non-statistically significant increase in
food intake. In our previous study, food intake was also
increased in association with increased energy expendi-
ture in leucine-treated DIO mice at the end of 14 week
study period, although in this particular model the
increase in food intake was apparently not sufficient to
offset the large increase in energy expenditure [7].
Conclusions
Altering dietary leucine intake has a significant impact on
energy metabolism. Chronic leucine supplementation
lowers HbA1c level and improves glucose and insulin
homeostasis in multiple mouse models of obesity and
diabetes. The metabolic benefits of leucine supplementa-
tion are associated with increased metabolic rates,
improved gene expression profile in skeletal muscle, and
decreased inflammation in adipose tissue, but are not
necessarily dependent of weight reduction.
Dietary intervention, either alone or as part of a thera-
peutic regimen, is important in the prevention and man-
agement of obesity and type 2 diabetes. Although the
physiology of human and mouse are clearly distinct, they
nonetheless share many common derangements in insu-
lin action and beta cell function that lead to type 2 diabe-
tes. Thus, increasing dietary leucine intake via leucine
supplementation may also prove beneficial to obese indi-
viduals susceptible to impaired glucose metabolism and
type 2 diabetes. The efficacy of leucine supplementation
in improving glucose-insulin homeostasis in obese
humans should be investigated.
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